ACADIA Pharmaceuticals

3611 Valley Centre Drive
Suite 300
San Diego
United States

Tel: 858-558-2871

Show jobs for this employer

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. 
In April 2016, ACADIA received FDA approval for NUPLAZID® (pimavanserin), the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including pimavanserin for dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and major depressive disorder and trofinetide for Rett syndrome.
Further information about ACADIA can be found at:

Stock Symbol: ACAD

Stock Exchange: NASDAQ

394 articles with ACADIA Pharmaceuticals